Detailed Information on Publication Record

MAUREL, Marine, Jennifer HOWARD, Esther KISSLING, Francisco POZO and Petr HUSA. Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024. EUROSURVEILLANCE. SWEDEN: EUR CENTRE DIS PREVENTION & CONTROL, 2024, vol. 29, No 8, p. 1-8. ISSN 1025-496X. Available from: https://dx.doi.org/10.2807/1560-7917.ES.2024.29.8.2400089.

Other formats: BibTeX LaTeX RIS

Basic information
Original name	Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
Authors	MAUREL, Marine (250 France, guarantor), Jennifer HOWARD (250 France), Esther KISSLING (250 France), Francisco POZO (724 Spain) and Petr HUSA (203 Czech Republic, belonging to the institution).
Edition	EUROSURVEILLANCE, SWEDEN, EUR CENTRE DIS PREVENTION & CONTROL, 2024, 1025-496X.

Other information
Original language	English
Type of outcome	Article in a journal
Field of Study	30303 Infectious Diseases
Country of publisher	Sweden
Confidentiality degree	is not subject to a state or trade secret
WWW	URL
Impact factor	Impact factor: 19.000 in 2022
Organization unit	Faculty of Medicine
Doi	http://dx.doi.org/10.2807/1560-7917.ES.2024.29.8.2400089
UT WoS	001198722300003
Keywords in English	Influenza A vaccine effectiveness; European primary care; hospital multicentre studies
Changed by	Changed by: prof. MUDr. Petr Husa, CSc., učo 945. Changed: 21/5/2024 13:40.

Abstract
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: −3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: −32 to 43), respectively.

Abstract

Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: −3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: −32 to 43), respectively.